Technical Analysis for MTEM - Molecular Templates, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 1.49 | -6.01% | -0.10 |
MTEM closed down 6.01 percent on Thursday, April 18, 2024, on 48 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Down 4 Days in a Row | Weakness | 0.00% | |
| Down 5 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -6.01% | |
| New 52 Week Low | Weakness | -6.01% |
| Alert | Time |
|---|---|
| Fell Below Lower Bollinger Band | about 17 hours ago |
| Lower Bollinger Band Support | about 18 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Down 5% | about 19 hours ago |
| 60 Minute Opening Range Breakout | about 21 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/13/2024
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies for the treatment of cancer and other serious diseases. It develops MT-3724, a lead drug candidate that is in a Phase 1 clinical trial in heavily pre-treated non-Hodgkin's lymphoma patients; MT-4019, a preclinical drug candidate targeting CD38; and evofosfamide, an investigational hypoxia-activated prodrug of a bis-alkylating agent that is preferentially activated under severe hypoxic tumor conditions, a feature of many solid tumors. The company is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Cancer Treatment Treatment Of Cancer Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Solid Tumors Cancer Treatment Treatment Of Cancer Oncology Chemical Elements Lymphoma Oxygen Toxins Prodrugs Evofosfamide Prodrug Nitrogen Mustards
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 9.45 |
| 52 Week Low | 1.45 |
| Average Volume | 76,913 |
| 200-Day Moving Average | 5.27 |
| 50-Day Moving Average | 2.81 |
| 20-Day Moving Average | 1.92 |
| 10-Day Moving Average | 1.80 |
| Average True Range | 0.25 |
| RSI (14) | 28.06 |
| ADX | 32.44 |
| +DI | 12.64 |
| -DI | 31.43 |
| Chandelier Exit (Long, 3 ATRs) | 2.03 |
| Chandelier Exit (Short, 3 ATRs) | 2.20 |
| Upper Bollinger Bands | 2.40 |
| Lower Bollinger Band | 1.45 |
| Percent B (%b) | 0.04 |
| BandWidth | 49.56 |
| MACD Line | -0.32 |
| MACD Signal Line | -0.33 |
| MACD Histogram | 0.0122 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.66 | ||||
| Resistance 3 (R3) | 1.67 | 1.62 | 1.63 | ||
| Resistance 2 (R2) | 1.62 | 1.58 | 1.62 | 1.62 | |
| Resistance 1 (R1) | 1.55 | 1.55 | 1.53 | 1.54 | 1.61 |
| Pivot Point | 1.50 | 1.50 | 1.49 | 1.50 | 1.50 |
| Support 1 (S1) | 1.43 | 1.46 | 1.41 | 1.43 | 1.36 |
| Support 2 (S2) | 1.38 | 1.43 | 1.38 | 1.35 | |
| Support 3 (S3) | 1.31 | 1.38 | 1.34 | ||
| Support 4 (S4) | 1.31 |
